Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB-3908 in healthy and mildly hypertensive subjects
NCT06501586Phase 1Completed
- Sponsor
- SanegeneBio
- Start
- Jul 2024
- Primary completion
- Apr 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) comparing SGB-3908 with Placebo (2 arms). Primary endpoint: Adverse Events at 12 months. Started Jul 2024; status: completed.
02
Drugs
IBI3016
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06501586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501586.